REGEN-COV becomes first monoclonal antibody treatment with EUA following exposure alone
By Molly Walker
FDA expanded the emergency use authorization (EUA) for the monoclonal antibody cocktail casirivimab and imdevimab, to include post-exposure prophylaxis (PEP) among certain people exposed to COVID-19, manufacturer Regeneron announced on Friday.
Casirivimab-imdevimab (REGEN-COV) is the first monoclonal antibody treatment that can be used either as a treatment for COVID-19 or after exposure but prior to a positive COVID-19 test, Regeneron said.
The new indication covers individuals ages 12 and older who were exposed to someone with the virus or who were exposed to the virus in an institutional setting.